What are you searching for?

06.06.2022 | Tracker

Product Launch Tracker: HCPs excited by approvals for Eli Lilly, Novartis, Sanofi and Regeneron

By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout May 2022 we tracked the global conversations of 2,197 HCPs who posted 3,094 English-language Twitter posts about the launches and approvals of new products.

Graph showing HCP mentions of product launches

Over the last month, HCPs discussed product approvals for the treatment of a variety of diseases including lymphoma, eosinophilic esophagitis and type 2 diabetes. In addition to this, new approvals related to COVID-19 also continued to catch HCPs’ attention, with the approval of Olumiant (baricitinib) as a COVID-19 treatment and the FDA’s expansion of the full approval of Pfizer’s booster vaccine to the 5-11 age group being key talking points.

The approval that generated the most conversation among HCPs in May was Regeneron and Sanofi’s Duxipent (dupilumab), which was approved by the FDA to treat eosinophilic esophagitis (EoE), a chronic disorder of the digestive system. As the first treatment for the condition to receive FDA approval, HCPs were excited to have a new approach to managing EoE.

HCPs also shared the approval of Eli Lilly’s Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes, which is targeted to improve blood sugar control in adults. HCPs highlighted this approval as an important milestone in the obesity treatment landscape and looked forward to seeing the treatment approved for weight management in the future too, noting impressive results from the SURMONT-1 trial.

Alongside these approvals, developments in the COVID-19 space also continued to engage HCPs, as they discussed FDA approval of Eli Lilly’s and Incyte’s Olumiant (baricitinib) for the treatment of certain hospitalised patients with COVID-19, becoming only the second drug to have full approval for treating the virus. Intensive care doctor Wesley Ely was at the forefront of HCPs conversations about the approval, drawing attention to the positive impact the drug has already had on treating patients during the pandemic and sharing some key facts about the treatment.

Finally, towards the end of May, the FDA approved Novartis’ Kymriah (tisagenlecleucel) CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma. This made it the second CAR-T cell therapy approved for lymphoma, alongside Yescarta (ciloleucel) and the second FDA approval for this drug. HCPs generally viewed this approval as good news and a positive advancement in lymphoma treatment.

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal

Methodology

  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 May and 30 May 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 May and 30 May 2022, there were 3,094 HCP mentions of new pharmaceutical product launches and drug approvals from 2,197 unique HCP authors from around the world.

View the latest and archived trackers here

 

View all articles >

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next


Pharma Strategy for virtual congress in 2020

23.04.2020 | Article

Pharma Strategy for virtual congress in 2020

Pharma Strategy for virtual congress in 2020

By Daniel Ghinn

Our enemy is fear, not #coronavirus

12.02.2020 | Article

Our enemy is fear, not #coronavirus

Our enemy is fear, not #coronavirus

By Daniel Ghinn

View all articles >